Navigation Links
FDA Approval of Ryanodex® Marks Milestone for Lyotropic Therapeutics
Date:8/6/2014

Richmond, Virginia (PRWEB) August 06, 2014

Lyotropic Therapeutics (Ashland, Virginia) today announced that its license partner, Eagle Pharmaceuticals, has received marketing approval by the U.S. Food and Drug Administration (FDA) for RYANODEX® (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. Ryanodex was developed and patented by Lyotropic Therapeutics and is licensed exclusively to Eagle Pharmaceuticals.

About Malignant Hyperthermia
MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. Once triggered, a rapidly progressing reaction involving sustained muscle contraction occurs with catastrophic consequences. Essential to the successful treatment of MH is the rapid institution of dantrolene sodium therapy and control of associated symptoms. Until now, dantrolene sodium preparation entailed a time-consuming reconstitution process and required several people for its preparation, a process that can take 15 to 20 minutes to mix, reconstitute and administer. Lyotropic Therapeutics developed Ryanodex to save critical time in preparation and administration of dantrolene sodium. Ryanodex can be prepared and administered in less than one minute by a single healthcare practitioner.

"Rapid administration of dantrolene sodium has long been recognized as key to reversal of MH. FDA approval of Ryanodex marks the availability of a major advance in the clinician’s ability to quickly prepare and deliver dantrolene sodium in the face of a fulminating MH crisis,” said Benjamin Cameransi, Jr., M.D., D.A.B.A., Vice President of Medical Affairs at Lyotropic Therapeutics. “In addition, approval of Ryanodex strongly validates the Company’s strategy of developing clinically significant new drugs backed with sound proof-of-concept data and then seeking a partner well positioned to complete product development and market the product.”

About Lyotropic Therapeutics
Lyotropic Therapeutics, Inc., based in Ashland, Virginia, is a pharmaceutical development company applying its substantial base of drug delivery technologies to develop unique, proprietary products with the goal of offering major therapeutic advances in patient safety and efficacy. The Company’s approach to product development and partnering has resulted in a significant portfolio of development stage injectable products in the field of anesthesia, pain management and critical care.

CONTACT:

for Lyotropic Therapeutics, Inc.

Vince Conklin, CEO
804.412.1030
vconklin(at)lyotropics(dot)com

Benjamin Cameransi, M.D. , D.A.B.A.,
Vice President of Medical Affairs
912.321.9112
bcameransi(at)lyotropics(dot)com
SOURCE Lyotropic Therapeutics, Inc.

Read the full story at http://www.prweb.com/releases/2014/08/prweb12072145.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
2. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
3. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
4. Savient Receives Approval From Bankruptcy Court To Sell Substantially All Assets To Crealta Pharmaceuticals
5. Perrigo Company And Elan Corporation plc Receive Irish High Court Approval For Perrigos Proposed Acquisition Of Elan
6. CSafe Global Celebrates Six-Year Anniversary of RKN FAA Approval and Launch of Fleet
7. Channel Medsystems Receives Health Canada Approval to Begin Clinical Evaluation of its Innovative Procedure for Heavy Menstrual Bleeding; Hires Mary Edwards as Senior Vice President, Clinical and Regulatory Affairs.
8. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
9. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
10. Humira and Simponi Have Been Prescribed By Significantly More U.S. Gastroenterologists in 2013 than in 2012, Likely Owing to Their Recent Approvals for Ulcerative Colitis
11. Profound Medical Receives IDE Approval from FDA to Conduct TULSA Clinical Trial for New Treatment for Localized Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):